Clearmind secures approval for AUD treatment trial in patients

Clearmind Medicine said on Wednesday it has received regulatory approval to initiate human trials for its investigational treatment targeting Alcohol Use Disorder (AUD).

The Israeli biotechnology company disclosed the clearance from the relevant health authority, allowing it to proceed with Phase I clinical testing in patients. The trial will assess the safety, tolerability and preliminary efficacy of the experimental therapy, which the firm has developed as a potential pharmaceutical intervention for AUD.

Clearmind did not disclose specific details about the trial design, patient enrollment timelines or primary endpoints in its announcement. The company has previously highlighted the treatment’s mechanism of action, which involves modulation of neural pathways associated with alcohol dependence, though further data was not provided.

The approval marks a significant milestone for Clearmind, which has focused on developing psychedelic-inspired therapies for central nervous system disorders. The company’s pipeline includes additional programs targeting other substance use disorders, though no regulatory clearances have been announced for those initiatives.

Shares of Clearmind Medicine were not immediately listed on major exchanges as of the announcement. The company trades over-the-counter in the United States under the ticker CMNDF.

Analysts noted that successful completion of the Phase I trial could pave the way for larger-scale studies and potential partnerships with pharmaceutical firms. However, they cautioned that early-stage drug development carries substantial risk, including high failure rates in clinical testing.

Clearmind has not provided financial guidance related to the AUD program’s development costs or potential revenue projections.